前立腺癌に対するEstramustine phosphatedisodium(Estracyt(R))の臨床的効果について

Abstract

前立腺癌患者40例を対象にEstracytの臨床的効果を検討した.投与量は1日4カプセル(分2)を原則とし, 3ヵ月間以上継続投与できたものについて検討を加えた.1)自覚症状では排尿困難に対する効果が最も良く, 夜間頻尿に対する効果がこれについでいた.他覚所見では残尿に対する効果が著明であったが, 前立腺局所に対する効果は40～50%であった.また, 既治療群に対する効果が比較的良好であった.3)副作用は乳房の変化が主なものでありその他に消化器症状も認めたが, 2例に狭心症様の発作をみており中止している

Estramustine phosphate disodium (Estracyt) was used in the treatment of 40 patients with prostatic carcinoma. Of these 20 patients 18 were treated with Estracyt as primary treatment and 22 had been treated with diethyl stilbestrol dephosphate and/or bilateral orchiectomy for more than 4 months before the Estracyt treatment. The drug was given orally in a dose of 560 mg/day in 2 divided oral doses. The clinical evaluation was done after 3 months treatment. The response in subjective symptoms and objective signs were documented and evaluated according to 5 criteria. In this study, Estracyt showed 80% improvement of dysuria, 60% of nykturia, 35% of pain and 55% of general condition. In objective signs, it showed 52.5% improvement of size of the prostate, 42.5% of consistency and 70% of residual urine. It would be emphasized that Estracyt had almost equal efficacy in both the primary treatment group and secondary treatment group. As side effects of this drug, gynecomastia, gastro-intestinal disturbance, angina pectoris like chest pain were observed.